New Perspectives in Thoracic Surgery for Malignant Pleural Mesothelioma

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 88

Special Issue Editor

E-Mail Website
Guest Editor
Thoracic Surgery—Morelli Hospital, ASST Valtellina e Alto Lario, 23100 Sondalo, Italy
Interests: lung cancer; pulmonary metastasis; pleural mesothelioma; innovative surgical techniques; minimally invasive thoracic surgery; VATS; surgical oncology; respiration physiology

Special Issue Information

Dear Colleagues,

Through the decades, mesothelioma surgery has been performed to diagnose disease, remove tumors (aggressive surgery such as extra-pleural pneumonectomy, or lung-sparing tumor-removing surgery, such as pleurectomy/decortication), or improve symptoms (palliative surgery). In a real-world multidisciplinary setting, many authors have reported that some long-term survivors benefit from surgery.

This Special Issue aims to understand what could happen in the future years, trying to foresee the trends in future  mesothelioma surgical treatments. We also would like to understand how to improve MDT, preoperative study, anesthesia, postoperative rehabilitation, palliation, and follow-up. Furthermore, is there a role for Artificial Intelligence in the treatment of mesothelioma? 

Simply put: should we leave surgery or could it still be somewhat useful? Which type of surgery, if any? It is widely recognized that a truly complete resection is not possible, and that neither an extrapleural pneumonectomy (EPP) nor a radical pleurectomy/decortication (P/D) can eradicate all residual microscopic tumour.

Recently, a strong debate has been going on following the IASLC presentation of the results of the MARS2 trial, which compared survival for two groups of pleural mesothelioma patients: one group had chemotherapy with surgery, and the other had chemo without surgery.

The MARS2 clinical study results were presented at the IASLC 2023 meeting, and the lead author, Dr.Lim, proposed eliminating surgery for patients affected by malignant pleural mesothelioma, so extending survival of 28%.

Dr. Lim stated: “Classifying this disease as [inoperable] from the outset would increase access to more effective systemic treatments to improve survival for patients with other stages of disease.”

However, the commentary of Dr. Ugalde Figueroa raised important questions about MARS2 data and analysis:

  • No true survival difference beetween the group: median survivals differed between the two groups, but not significantly.
  • Patient characteristics were unequal between groups: the surgery group had a higher percentage of patients with significant risk factors, possibly leading to an increase in postoperative unfavourable outcome.
  • The treating hospitals lacked experience: “Would the outcome be different in exclusively high-volume centers?”

We are solicitings clinical trials’ reports or projects, study designs, case series, technical “how-to-do-it” articles, narrative and systematic reviews, expert commentaries.

Dr. Paolo Scanagatta
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • thoracic medicine
  • thoracic surgery
  • pleural mesothelioma
  • chemotherapy
  • oncology
  • thoracic anesthesia

Published Papers

This special issue is now open for submission.
Back to TopTop